On the ADC front, Innovent’s CLDN18.2-targeted arcotatug tavatecan (IBI-343) cleared another milestone after interim Phase III results in G-Hope-001, with the company submitting an NDA to China’s NMPA and securing priority review for previously treated advanced gastric cancer. The filing centers on patients receiving at least two prior systemic therapies. ADC commercial and safety scrutiny also intensified as ADC Therapeutics faced confirmatory-trial pressure in DLBCL. The company reported elevated death rates in the Lotis-5 confirmatory study testing Zynlonta plus rituximab, with analysts flagging the impact on perceived clinical value and the path toward full approval.